43742-2123 NDC - VIR COMBINATION (ADENOVIREN NOSODE, CYTOMEGALOVIRUS NOSODE, HERPES SIMPLEX VIRUS 1 DNA, HERPES SIMPLEX VIRUS 2 DNA, EPSTEIN-BARR VIRUS NOSODE, HEPATITIS B NOSODE, HERPES SIMPLEX 1 NOSODE, HERPES SIMPLEX 2 NOSODE, HUMAN HERPESVIRUS 6A, HUMAN HERPESVIRUS 6B, INFLUENZINUM (2022-2023))

Drug Information

  • Product NDC: 43742-2123
  • Proprietary Name: Vir Combination
  • Non Proprietary Name: Adenoviren Nosode, Cytomegalovirus Nosode, Herpes Simplex Virus 1 DNA, Herpes Simplex Virus 2 DNA, Epstein-Barr Virus Nosode, Hepatitis B Nosode, Herpes Simplex 1 Nosode, Herpes Simplex 2 Nosode, Human Herpesvirus 6A, Human Herpesvirus 6B, Influenzinum (2022-2023)
  • Active Ingredient(s): 33 [hp_X]/mL HEPATITIS B VIRUS; 12 [hp_C]/mL HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 ANTIGEN; 12 [hp_X]/mL HUMAN HERPESVIRUS 1; 12 [hp_X]/mL HUMAN HERPESVIRUS 2; 16 [hp_C]/mL HUMAN HERPESVIRUS 4; 18 [hp_X]/mL HUMAN HERPESVIRUS 5; 15 [hp_X]/mL HUMAN HERPESVIRUS 6; 12 [hp_X]/mL INFLUENZA A VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED); 12 [hp_X]/mL INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED); 12 [hp_X]/mL INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 ANTIGEN (UV, FORMALDEHYDE INACTIVATED); 12 [hp_X]/mL INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (UV, FORMALDEHYDE INACTIVATED)
  • Administration Route(s): ORAL
  • Dosage Form(s): LIQUID
  • Pharmacy Class(es): Actively Acquired Immunity [PE]; Live Human Adenovirus Type 4 Vaccine [EPC]; Vaccines; Adenovirus [Chemical/Ingredient]; Vaccines; Live; Unattenuated [Chemical/Ingredient]

Labeler Information

Field Name Field Value
Labeler Name: Deseret Biologicals, Inc.
Product Type: HUMAN OTC DRUG
FDA Application Number:
Marketing Category: UNAPPROVED HOMEOPATHIC
Start Marketing Date:1/25/2024
End Marketing Date:3/20/2029

Package Information

No. Package Code Package Description Billing Unit
143742-2123-130 mL in 1 BOTTLE, DROPPER (43742-2123-1)

NDC Record

Field Name Field Value Definition
PRODUCT NDC43742-2123The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN OTC DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEVir CombinationThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEAdenoviren Nosode, Cytomegalovirus Nosode, Herpes Simplex Virus 1 DNA, Herpes Simplex Virus 2 DNA, Epstein-Barr Virus Nosode, Hepatitis B Nosode, Herpes Simplex 1 Nosode, Herpes Simplex 2 Nosode, Human Herpesvirus 6A, Human Herpesvirus 6B, Influenzinum (2022-2023)The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMELIQUIDThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE1/25/2024This is the date that the labeler indicates was the start of its marketing of the drug product.
END MARKETING DATE3/20/2029This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
MARKETING CATEGORY NAMEUNAPPROVED HOMEOPATHICProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
LABELER NAMEDeseret Biologicals, Inc.Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEHEPATITIS B VIRUS; HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 ANTIGEN; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5; HUMAN HERPESVIRUS 6; INFLUENZA A VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED); INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED); INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 ANTIGEN (UV, FORMALDEHYDE INACTIVATED); INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (UV, FORMALDEHYDE INACTIVATED)An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH33; 12; 12; 12; 16; 18; 15; 12; 12; 12; 12 
ACTIVE INGRED UNIT[hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL 
PHARM CLASSESActively Acquired Immunity [PE], Live Human Adenovirus Type 4 Vaccine [EPC], Vaccines, Adenovirus [Chemical/Ingredient], Vaccines, Live, Unattenuated [Chemical/Ingredient] 

Download Record

Download this NDC record record in Text format: Export

Download this NDC record record in Excel (CSV) format: Export

Download this NDC record record in XML format: Export

This page was last updated on: 7/4/2025

Previous Code
Next Code